Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Tevogen highlights capital discipline, minimal share use, strong insider ownership, and potential acquisitions while exploring ways to reflect asset value
-
Introducing Rozum: an AI reasoning engine built for high-stakes decisions - and the highest-scoring system on Humanity's Last Exam. Now in early access.
-
Claret Capital Partners, Europe's largest independent growth debt fund manager has made an investment, through its Fund IV, of up to EUR 28m
-
Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game.
-
Easy Environmental Solutions surges to great start in first quarter of 2026
-
Cbio gets EMA approval to start its phase I/IIa clinical trial in late stage cancer patients with novel T-cell product armored against oxidative stress
-
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
-
AI, healthcare technology, and digital infrastructure is a central theme dominating markets: the rapid convergence of AI with data-heavy industries
-
Unicorns are usually $1 billion private companies, backed by institutional players and Kraig Labs (OTCQB: KBLB) is advancing a $billion platform
-
NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today reinforced how its strategic investment in PsyLabs strengthens its...